Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 26/06/2024 BST			5-day change	1st Jan Change
1,791 ^DKK	-0.44%		+1.94%	-16.89%

06-10	Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
06-04	Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating	MT

Genmab A/S Elects Mats Pettersson to the Board of Directors

April 17, 2013 at 03:19 pm

Genmab A/S elected Mats Pettersson to the Board of Directors for a one year period.

Latest news about Genmab A/S

Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM	06-10
Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating	06-04	MT
Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study	06-03	MT
Transcript : Genmab A/S - Special Call	06-03
Genmab A/S Announces Data from the Phase 2 Innovatv 207 Trial, Investigating Tisotumab Vedotin	06-03	CI
Genmab A S and BioNTech SE Announces Initial Data from the Ongoing Phase 2 Trial	06-03	CI
Genmab Announces Initial Data from Phase 2 Cancer Treatment Trial	06-03	MT
Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma	06-02	CI
Genmab A/S and Biontech SE Announce Initial Data from the Phase 2 Gct1046-04 Trial (NCT05117242) Evaluating Acasunlimab	06-01	CI
Genmab A/S Reaffirms Financial Guidance for 2024	05-21	CI
Genmab A/S completed the acquisition of ProfoundBio, Inc.	05-20	CI
Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'	05-15	MT
Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50%	05-15	MT
Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association Congress	05-14	CI
GENMAB : A good start to 2024; guidance unchanged	05-03
Genmab Posts Q1 Net Profit Surge; Revenue Jumps	05-03	MT
Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance	05-02	MT
Transcript : Genmab A/S, Q1 2024 Earnings Call, May 02, 2024	05-02
Tranche Update on Genmab A/S's Equity Buyback Plan announced on March 1, 2021.	05-02	CI
Tranche Update on Genmab A/S's Equity Buyback Plan announced on March 25, 2024.	05-02	CI
Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer	04-30	MT
Genmab, Pfizer Win US FDA Approval for Cervical Cancer Treatment	04-30	MT
Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer	04-29	CI
Pfizer, Genmab Get Full FDA Approval for Cervical-Cancer Drug	04-29	DJ

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 06:08 pm

More Strategies

Ratings for Genmab A/S

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,799 DKK

Average target price

2,464 DKK

Spread / Average Target

+36.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GENMAB A/S	-16.89%	16.43B
VERTEX PHARMACEUTICALS INCORPORATED	+16.49%	122B
REGENERON PHARMACEUTICALS, INC.	+21.43%	116B
ARGENX SE	+22.18%	27.03B
BIONTECH SE	-21.36%	20.36B
BEIGENE, LTD.	-18.13%	15.91B
WUXI APPTEC CO., LTD.	-44.74%	15.6B
SAREPTA THERAPEUTICS, INC.	+61.98%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+3.29%	13.59B
INSMED INCORPORATED	+122.65%	11.24B

Bio Therapeutic Drugs

Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Genmab A/S Elects Mats Pettersson to the Board of Directors

Latest news about Genmab A/S

Chart Genmab A/S

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Genmab A/S

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs